» Articles » PMID: 33788883

Prognostic and Clinicopathological Significance of GPRC5A in Various Cancers: A Systematic Review and Meta-analysis

Overview
Journal PLoS One
Date 2021 Mar 31
PMID 33788883
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Background: GPRC5A is associated with various cancer initiation and progression. Controversial findings have been reported about GPRC5A prognostic characteristics, and no meta-analysis has been conducted to assess the relationship between GPRC5A and cancer prognosis. Therefore, the objective of this meta-analysis is to evaluate the overall prognostic effectiveness of GPRC5A.

Methods: We first conducted a systematic search in the PubMed, Embase, Web of Science, CNKI, Cochrane, and WangFang databases. The hazard ratio (HR) and odds ratios (OR) with 95% CI were then pooled to assess the associations between GPRC5A expression and overall survival (OS), disease-free survival (DFS), event-free survival (EFS), and clinicopathological characteristics. Chi-squared test and I2 statistics were completed to evaluate the heterogeneity in our study. A random-effects model was used when significant heterogeneity existed (I2>50% and p<0.05); otherwise, we chose the fixed-effect model. Subgroup analysis was stratified by tumor type, region, HR obtained measurements, and sample capacity to explore the source of heterogeneity.

Results: In total, 15 studies with 624 patients met inclusion criteria of this study. Our results showed that higher expression of GPRC5A is associated with worse OS (HR:1.69 95%CI: 1.20-2.38 I2 = 75.6% p = 0.000), as well as worse EFS (HR:1.45 95%CI: 1.02-1.95 I2 = 0.0% p = 0.354). Subgroup analysis indicated that tumor type might be the source of high heterogeneity. Additionally, cancer patients with enhanced GPRC5A expression were more likely to lymph node metastasis (OR:1.95, 95%CI 1.33-2.86, I2 = 43.9%, p = 0.129) and advanced tumor stage (OR: 1.83, 95%CI 1.15-2.92, I2 = 61.3%, p = 0.035), but not associated with age, sex, differentiation, and distant metastasis.

Conclusion: GPRC5A can be a promising candidate for predicting medical outcomes and used for accurate diagnosis, prognosis prediction for patients with cancer; however, the predictive value of GPRC5A varies significantly according to cancer type. Further studies for this mechanism will be necessary to reveal novel insights into application of GPRC5A in cancers.

Citing Articles

Endogenous and Exogenous Regulatory Signaling in the Secretory Pathway: Role of Golgi Signaling Molecules in Cancer.

Del Giudice S, De Luca V, Parizadeh S, Russo D, Luini A, Di Martino R Front Cell Dev Biol. 2022; 10:833663.

PMID: 35399533 PMC: 8984190. DOI: 10.3389/fcell.2022.833663.

References
1.
El Gammal A, Melling N, Reeh M, Gebauer F, Mann O, Perez D . High levels of RAI3 expression is linked to shortened survival in esophageal cancer patients. Exp Mol Pathol. 2019; 107:51-56. DOI: 10.1016/j.yexmp.2019.01.013. View

2.
Jahny E, Yang H, Liu B, Jahnke B, Lademann F, Knosel T . The G Protein-Coupled Receptor RAI3 Is an Independent Prognostic Factor for Pancreatic Cancer Survival and Regulates Proliferation via STAT3 Phosphorylation. PLoS One. 2017; 12(1):e0170390. PMC: 5256936. DOI: 10.1371/journal.pone.0170390. View

3.
Fujimoto J, Kadara H, Garcia M, Kabbout M, Behrens C, Liu D . G-protein coupled receptor family C, group 5, member A (GPRC5A) expression is decreased in the adjacent field and normal bronchial epithelia of patients with chronic obstructive pulmonary disease and non-small-cell lung cancer. J Thorac Oncol. 2012; 7(12):1747-1754. PMC: 3622592. DOI: 10.1097/JTO.0b013e31826bb1ff. View

4.
Golay J, DAmico A, Borleri G, Bonzi M, Valgardsdottir R, Alzani R . A novel method using blinatumomab for efficient, clinical-grade expansion of polyclonal T cells for adoptive immunotherapy. J Immunol. 2014; 193(9):4739-47. DOI: 10.4049/jimmunol.1401550. View

5.
Jin E, Wang W, Fang M, Wang W, Xie R, Zhou H . Clinical significance of reduced GPRC5A expression in surgically resected non-small cell lung cancer. Oncol Lett. 2019; 17(1):502-507. PMC: 6313189. DOI: 10.3892/ol.2018.9537. View